February 2018 - Volume 28 - Issue 1 - Contributor Index

Alphabetical Search
F
Y
Author:
Adams, David J.
Author:
Alani, Rhoda M.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Arends, Mark J.
Author:
Arjyal, Lubina
Author:
Awasthi, Sanjay

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Batty, Nicolas

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Bhawan, Jag
Author:
Bista, Amir
Author:
Branca, Mattia
Author:
Brenn, Thomas

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Author:
Busam, Klaus J.
Author:
Chesney, Jason

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Chung, Hye J.
Author:
Curti, Brendan

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Author:
Heimann, Pierre

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Author:
Hogg, David
Author:
Hutchins, Laura

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Jansen, Yanina

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Author:
Jay, Samuel
Author:
Kaatz, Martin

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Kuo, James C.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Author:
Linette, Gerald

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Lutzky, Jose

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Marczak, Michal

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Mili, Nabil

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Neyns, Bart

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Author:
Niroula, Abesh
Author:
Orso, Samuel

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Planken, Simon

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Potemski, Piotr

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Author:
Qin, You

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Ryu, Byungwoo
Author:
Sabo, Tibor J.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Schreuer, Max

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from...

Seremet, Teofila; Planken, Simon; Schreuer, Max; More

Melanoma Research. 28(1):65-70, February 2018.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Author:
Smith, Angela

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Tang, Yong

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

Author:
Triozzi, Pierre

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Tuting, Thomas
Author:
Uprety, Dipesh
Author:
Whitman, Eric

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective...

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; More

Melanoma Research. 28(1):44-51, February 2018.

Author:
Xie, Chao
Author:
Xu, Haotian
Author:
Zhang, Qing
Author:
Zhang, Weikang
Author:
Zhang, Yu
Author:
Zhang, Yuming

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

1 2 3 4 5